Register for our upcoming webinar or watch recordings of previous webinars below:

Making Safety a Part of Drug Design
13 November 2018

<br>Antibacterial drugs: Clinical development for non-developers </br> Part 2: Development of antibacterial drugs targeting specific pathogens — Antibacterial drugs: Clinical development for non-developers Part 2: Development of antibacterial drugs targeting specific pathogens
11 September 2018

PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?
26 June 2018

<br>Antibacterial drugs: Clinical development for non-developers </br> Part 1: Traditional development – tiers A and B — Antibacterial drugs: Clinical development for non-developers Part 1: Traditional development – tiers A and B
13 June 2018

« Previous
1
2
3

Share

facebook twitter linkedin reddit Email

REVIVE

REVIVE is a space for everybody with an interest in antimicrobial R&D.

The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit organization developing new treatments for drug-resistant infections that pose the greatest threat to health. We were created to ensure that everyone who needs antibiotics receives effective and affordable treatment, no matter where they live. We aim to develop five new treatments by 2025 to fight drug-resistant infections, focusing on sexually transmitted infections, sepsis in newborns and infections in hospitalized adults and children.

Content

Antimicrobial Viewpoints (23)
Conferences (16)
Experts (87)
External webinars (14)
Uncategorized (2)
Webinars (28)

Search site

Search for:

CONNECT

Twitter
LinkedIn
YouTube

GARDP
DNDi

Privacy Policy | Terms of Use | Acceptable Use Policy | Cookie Policy

We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser.
Read our cookie policy

Webinars

Register for our upcoming webinar or watch recordings of previous webinars below:

Making Safety a Part of Drug Design

Antibacterial drugs: Clinical development for non-developers Part 2: Development of antibacterial drugs targeting specific pathogens

PK-PD in support of accelerated programmes for antimicrobial development: how much is enough?

Antibacterial drugs: Clinical development for non-developers Part 1: Traditional development – tiers A and B

Share